(Reuters) – The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals’ drug-device combination to treat movement-related symptoms of Parkinson’s disease, the drugmaker said on Monday.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
